India and Uzbekistan Launches Pharma-Nutraceutical Corridor for Eurasian Market
In March 2026, India and Uzbekistan jointly launched a structured pharmaceutical and nutraceutical corridor designed to expand access to the Commonwealth of Independent States (CIS) and the wider Eurasian healthcare market, estimated to be worth USD 7–10 billion.
About Pharma-Nutraceutical Corridor:
Partnership: The trade corridor was formalised through a partnership between the Ministry of Health of the Republic of Uzbekistan, Nutrify Today, Bengaluru(Karanataka)-based nutraceutical platform), and Pharma Eurasia, a trade and exhibition platform headquartered in Tashkent, Uzbekistan.
Purpose: The Indo–CIS Pharma-Nutraceutical Corridor is a policy-backed platform to promote regulatory alignment, trade facilitation, investment, and commercial engagement between India and the CIS/Eurasian region.
Commercial Launch: The corridor will be commercially activated at Pharma Eurasia 2026, a major industry exhibition scheduled from 20–22 May 2026 in Tashkent, Uzbekistan.
Operational Focus: The corridor will support companies through regulatory harmonisation, supply chain digitisation, investment facilitation, joint ventures, Research and Development (R&D) collaboration, and trade matchmaking to enable seamless market entry and commercialisation.
In March 2026, India and Uzbekistan jointly launched a structured pharmaceutical and nutraceutical corridor designed to expand access to the Commonwealth of Independent States (CIS) and the wider Eurasian healthcare market, estimated to be worth USD 7–10 billion.
About Pharma-Nutraceutical Corridor:
Partnership: The trade corridor was formalised through a partnership between the Ministry of Health of the Republic of Uzbekistan, Nutrify Today, Bengaluru(Karanataka)-based nutraceutical platform), and Pharma Eurasia, a trade and exhibition platform headquartered in Tashkent, Uzbekistan.
Purpose: The Indo–CIS Pharma-Nutraceutical Corridor is a policy-backed platform to promote regulatory alignment, trade facilitation, investment, and commercial engagement between India and the CIS/Eurasian region.
Commercial Launch: The corridor will be commercially activated at Pharma Eurasia 2026, a major industry exhibition scheduled from 20–22 May 2026 in Tashkent, Uzbekistan.
Operational Focus: The corridor will support companies through regulatory harmonisation, supply chain digitisation, investment facilitation, joint ventures, Research and Development (R&D) collaboration, and trade matchmaking to enable seamless market entry and commercialisation.
Sponsored Advertisement
No comments yet. Be the first!